New Delhi: The supply price of COVID-19 vaccine Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run, Bharat Biotech said on Tuesday.
The Centre’s supplying price is pushing the pricing structure for the private sector upward, the vaccine maker said, justifying Covaxin’s higher price when compared to other COVID-19 vaccines available for the private sector in India.
According to the company, fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among others were contributing to higher pricing of Covaxin.
“The supply price of Covaxin to the government of India at Rs 150 per dose is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs,” Bharat Biotech said in a statement.
